HER-2 and cancer antigen 125 evaluation in ovarian borderline tumors by immunohistochemistry and fluorescence in situ hybridization

International Journal of Gynecological Cancer

Volumn 14, Issue 6, 2004, Pages 1078-1085

  Heinrich, J K R ^a   Bottcher Luiz F ^a   Andrade, L L A ^b   Davidson, S ^c   Bonds, L ^c   Stephens, J ^c   Varella Garcia, M ^c  

^a CAISM   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

Borderline ovarian tumors; CA 125; FISH; HER 2; IHC

Indexed keywords

CANCER ANTIGEN 125; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; ASSAY; CANCER GROWTH; CHROMOSOME 17; CONTROLLED STUDY; DNA PROBE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ONCOGENE NEU; OVARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOCARCINOMA, MUCINOUS; CA-125 ANTIGEN; CASE-CONTROL STUDIES; CYSTADENOCARCINOMA, SEROUS; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; OVARIAN NEOPLASMS; PARAFFIN EMBEDDING; PREDICTIVE VALUE OF TESTS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 10044270836     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1048-891X.2004.14605.x     Document Type: Article

References (35)

1. Link CJ Jr, Reed E, Sarosy G, Kohn EC. Borderline ovarian tumors. Am J Med 1996;101:217-25.
2. Barakat RR. Borderline tumors of the ovary. Obstet Gynecol Clin North Am 1994;21:93-105.
3. Trope C, Kaern J. Management of borderline tumors of the ovary: state of the art. Semin Oncol 1998;25:372-80.
4. Link CJ Jr, Kohn E, Reed E. The relationship between borderline ovarian tumors and epithelial ovarian carcinoma: epidemiologic, pathologic and molecular aspects. Gynecol Oncol 1996;60:347-54.
5. Buttin BM, Herzog TJ, Powell MA, Rader JS, Mutch DG. Epithelial ovarian tumors of low malignant potential: the role of microinvasion. Obstet Gynecol 2002;99:11-7.
6. Puls LE, Powell D, DePriest PD et al. Transition from benign to malignant epithelium in mucinous and serous ovarian cystadenocarcinoma. Gynecol Oncol 1992;47:53-7.
7. Diebold J, Deisenhofer I, Baretton GB et al. Interphase cytogenetic analysis of serous ovarian tumors of low malignant potential: comparison with serous cystadenomas and invasive serous carcinomas. Lab Invest 1996;75:473-85.
8. Bell DA, Scully RE. Ovarian serous borderline tumors with stromal microinvasion: a report of 21 cases. Hum Pathol 1990;21:397-403.
9. Watson RH, Neville PJ, Roy WJ, Hitchcock A, Campbell IG. Loss of heterozygosity on chromosomes 7p, 7q, 9p and 11q is an early event in ovarian tumorigenesis. Oncogene 1998;17:207-12.
10. Yin BW, Lloyd KO. Molecular cloning of the CA 125 ovarian cancer antigen: identification as a new mucin, MUC16. J Biol Chem 2001;276:27371-5.
11. Yin BW, Dnistrian A, Lloyd KO. Ovarian cancer antigen CA 125 is encoded by the MUC 16 mucin gene. Int J Cancer 2002;98:737-40.
12. Bast RC, Klug TL, St-John E et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1981;309:883-7.
13. Nagele F, Petru E, Medl M, Kainz C, Graf AH, Sevelda P. Preoperative CA 125: an independent prognostic factor in patients with stage I epithelial ovarian cancer. Obstet Gynecol 1995;86:259-64.
14. Friedlander ML. Prognostic factors in ovarian cancer. Semin Oncol 1998;25:305-14.
15. Mogensen O. Prognostic value of CA 125 in advanced ovarian cancer. Gynecol Oncol 1992;4:207-12.
16. Frasci G, Conforti S, Zullo F et al. A risk model for ovarian carcinoma patients using CA 125: time to normalization renders second-look laparotomy redundant. Cancer 1996; 77:1122-30.
17. Popescu NC, King CR, Kraus MH. Localization of the human erb B-2 gene on normal and rearranged chromosomes 17 to bands q12-21.3. Genomics 1989;4:362-6.
18. Berchuck A, Kohler MF, Hopkins MP et al. Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors. Gynecol Oncol 1994;52:232-5.
19. Meden H, Marx D, Rath W et al. Overexpression of the oncogene c-erb B2 in primary ovarian cancer: evaluation of the prognostic value in a Cox proportional hazards multiple regression. Int J Gynecol Pathol 1994; 13:45-53.
20. Tanner B, Kreutz E, Weikel W et al. Prognostic significance of c-erB-2 mRNA in ovarian carcinoma. Gynecol Oncol 1996;62:268-77.
21. Rubin SC, Finstad CL, Wong GY, Almadrones L, Plante M, Lloyd KO. Prognostic significance of HER-2 expression in advanced epithelial ovarian cancer: a multivariate analysis. Am J Obstet Gynecol 1993;168:162-9.
22. Goff BA, Muntz HG, Greer BE, Tamimi HK, Gown AM. Oncogene expression: long-term compared with short-term survival in patients with advanced epithelial ovarian cancer. Obstet Gynecol 1998;92:88-93.
23. Ross JS, Yang F, Kallakury BV, Sheehan CE, Ambros RA, Muraca PJ. HER-2 oncogene amplification by fluorescence in situ hybridization in epithelial tumors of the ovary. Am J Clin Pathol 1999;111:311-6.
24. Kacinski BM, Mayer AG, King BL, Carter D, Chambers SK. NEU protein Overexpression in benign, borderline, and malignant ovarian neoplasms. Gynecol Oncol 1992;44:245-53.
25. Fajac A, Benard J, Lhomme C et al. c-erbB2 gene amplification and protein expression in ovarian epithelial tumors: evaluation of their respective prognostic significance by multivariate analysis. Int J Cancer 1995;64:146-51.
26. Fritsche HA, Bast RC. CA 125 in ovarian cancer: advances and controversy. Clin Chem 1998;44:1379-80.
27. Rump A, Morikawa Y, Tanaka M et al. Binding of ovarian cancer antigen CA125/MUC 16 to mesothelin mediates cell adhesion. J Biol Chem 2004;279:9190-8.
28. Schlosshauer PW, Cohen CJ, Penault-Lorca F, Miranda CR, Dauplat J, Deligdisch L. Prophylatic oophrectomy: a morphologic and immunohistochemical study. Cancer 2003;98:2599-606.
29. Kakar S, Puangsuvan N, Stevens JM, Serenas R, Mangan G. Comparison of PathVysion and INFORM fluorescence in situ hybridization. Mol Diagn 2000;5:193-7.
30. Slamon DJ, Leyland-Jones B, Shak S. Addition of Herceptin (humanized anti HER-2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer markedly increases anticancer activity: a randomized, multinational controlled phase III trial. Proc Am Soc Clin Oncol 1998;17:98a.
31. Taguchi T, Zhou JY, Feder M, Litwin S, Klein-Szanto AJ, Testa JR. Detection of aneuploidy in interphase nuclei from non-small cell lung carcinomas by fluorescence in situ hybridization using chromosome-specific repetitive DNA probes. Cancer Genet Cytogenet 1996;89:120-5.
32. Ai H, Barrera JE, Pan Z, Meyers AD, Varella-Garcia M. Identification of individuals at high risk for head and neck carcinogenesis using chromosome aneuploidy detected by fluorescence in situ hybridization. Mutat Res 1999;439:223-32.
33. Mylonas I, Makovitzky J, Richter DU, Jeschke U, Briese V, Friese K. Immunohistochemical expression of the tumor marker CA-125 in normal, hyperplastic and malignant endometrial tissue. Anticancer Res 2003;23: 1075-80.
34. Rice LW, Lage JM, Berkowitz RS et al. Preoperative serum CA-125 levels in borderline tumors of the ovary. Gynecol Oncol 1992;46:226-9.
35. Eltabbakh GH, Natarajan N, Piver MS, Mettlin CJ. Epidemiologic differences between women with borderline ovarian tumors and women with epithelial ovarian cancer. Gynecol Oncol 1999;74:103-7.